Product image of Imuldosa (Ustekinumab) supplied by GNH India

Imuldosa

Active Ingredient:
Ustekinumab
Origin:
EU

Imuldosa (Ustekinumab)

Ustekinumab, the active ingredient in Imuldosa, is a Interleukin-12/23 inhibitor presented as an intravenous formulation for use in adults with moderate to severe plaque psoriasis, psoriatic arthritis, or Crohn's disease. It targets key inflammatory pathways to reduce disease activity.

GNH India supplies Imuldosa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Accord Healthcare Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Imuldosa is an interleukin‑12/23 inhibitor indicated for several chronic inflammatory conditions.
  • Plaque psoriasis: reduces skin lesions and inflammation.
  • Psoriatic arthritis: improves joint symptoms and helps prevent structural damage.
  • Moderate to severe Crohn's disease: induces and maintains remission of intestinal inflammation.

How It Works

  • Ustekinumab binds with high affinity to the p40 subunit shared by interleukin‑12 and interleukin‑23, blocking their interaction with cell‑surface receptors. This inhibition suppresses the Th1 and Th17 pathways, leading to decreased production of downstream pro‑inflammatory cytokines and modulation of the immune response that drives psoriasis, psoriatic arthritis, and Crohn's disease.

Side Effects

Common Side Effects

  • Injection site reactions: redness, swelling, or pain at the infusion site.
  • Nasopharyngitis: mild upper‑respiratory tract infection symptoms.
  • Headache: transient mild to moderate headache.
  • Fatigue: feeling unusually tired.
  • Diarrhea: loose stools without severe dehydration.
  • Upper respiratory infection: cough, sore throat, or congestion.

Serious or Rare Side Effects

  • Serious infections: tuberculosis, fungal, or opportunistic infections.
  • Malignancies: potential increased risk of certain cancers.
  • Hypersensitivity reactions: anaphylaxis, urticaria, or angioedema.
  • Exacerbation of inflammatory bowel disease: worsening of Crohn's symptoms.
  • Demyelinating disease: new or worsening neurologic disorders.
  • Cardiac events: rare cases of myocardial infarction or heart failure.

Precautions & Warnings

  • Before initiating therapy, clinicians should evaluate patient history and monitor for specific risks.
  • Screen for active infections: assess and treat any current infection prior to the first dose.
  • Monitor for signs of infection: advise patients to report fever, cough, or unexplained illness.
  • Assess tuberculosis risk: perform TB screening and treat latent infection when indicated.
  • Consider vaccination status: administer required vaccines before starting therapy.
  • Pregnancy and lactation: discuss potential risks with the healthcare provider.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Ustekinumab may interact with other agents that affect immune function or vaccine efficacy.

Major Interactions (Avoid)

  • Live vaccines: contraindicated during treatment.
  • Concurrent immunosuppressants (e.g., azathioprine, methotrexate): may increase infection risk.
  • Cytokine modulators (e.g., interferon): potential additive immunosuppression.

Moderate Interactions (Monitor Closely)

  • Non‑live vaccines: may have reduced efficacy, monitor immune response.
  • Antibiotics for active infection: consider temporary discontinuation of ustekinumab.
  • Cytochrome P450 substrates: generally minimal effect, but monitor levels if clinically relevant.

Frequently Asked Questions

Imuldosa, containing ustekinumab, is approved for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and moderate to severe Crohn's disease in adults. It is used when conventional systemic therapies have not provided adequate disease control.

Ustekinumab binds to the p40 subunit shared by interleukin‑12 and interleukin‑23, preventing these cytokines from interacting with their receptors on immune cells. This blocks the Th1 and Th17 inflammatory pathways, reducing the release of downstream pro‑inflammatory mediators that drive skin, joint, and intestinal inflammation.

The dosing schedule for Imuldosa is individualized by the prescribing clinician based on the patient’s body weight, disease severity, and response to therapy. Initial loading doses are followed by maintenance infusions at intervals defined by the treating physician.

Safety data for ustekinumab in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant, and decisions should be made in consultation with a qualified healthcare professional.

To order Imuldosa, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics), and necessary import documentation.

Imuldosa (ustekinumab) targets interleukin‑12/23, whereas many alternatives target tumor necrosis factor‑α or interleukin‑17. Clinical studies show comparable efficacy in skin clearance, with a dosing schedule that may be less frequent than some IL‑17 inhibitors. Safety profiles differ, particularly regarding infection risk and potential malignancy concerns.

Imuldosa should be stored refrigerated at 2‑8 °C. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. Do not use if the solution appears discolored or contains particles.

Imuldosa is given by intravenous infusion under the supervision of a qualified healthcare professional. The initial dose is typically administered as a weight‑based loading infusion, followed by maintenance infusions at intervals determined by the prescriber, often every 8 to 12 weeks.

The most serious risks include severe infections such as tuberculosis or opportunistic pathogens, potential development of malignancies, hypersensitivity reactions including anaphylaxis, and possible exacerbation of inflammatory bowel disease. Patients should be monitored closely for any signs of infection or unusual symptoms.

Imuldosa is contraindicated in individuals with known hypersensitivity to ustekinumab or any of its excipients, and it should be avoided in patients with active, uncontrolled infections. Caution is also advised for those with a history of malignancy, demyelinating disorders, or severe heart failure.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ustekinumab

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT